Now showing items 154-173 of 652

    • DAISY: picking synthetic lethals from cancer genomes. 

      Ryan, CJ; Lord, CJ; Ashworth, A (2014-09)
      A better understanding of genetic interactions in cancer might help identify new therapeutic approaches that exploit the concept of synthetic lethality. Ruppin and colleagues have developed a new computational method, ...
    • A decade of clinical development of PARP inhibitors in perspective. 

      Mateo, J; Lord, CJ; Serra, V; Tutt, A; Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; Oaknin, A; Kaye, SB; de Bono, JS (2019-09-01)
      Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce ...
    • Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. 

      Li, H; Stokes, W; Chater, E; Roy, R; de Bruin, E; Hu, Y; Liu, Z; Smit, EF; Heynen, GJ; Downward, J; Seckl, MJ; Wang, Y; Tang, H; Pardo, OE (2016)
      Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through ...
    • Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis. 

      Morfopoulou, S; Mee, ET; Connaughton, SM; Brown, JR; Gilmour, K; Chong, WKK; Duprex, WP; Ferguson, D; Hubank, M; Hutchinson, C; Kaliakatsos, M; McQuaid, S; Paine, S; Plagnol, V; Ruis, C; Virasami, A; Zhan, H; Jacques, TS; Schepelmann, S; Qasim, W; Breuer, J (2017-01)
      Routine childhood vaccination against measles, mumps and rubella has virtually abolished virus-related morbidity and mortality. Notwithstanding this, we describe here devastating neurological complications associated with ...
    • Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPK alpha 2 but not AMPK alpha 1 

      Ashworth, A (2006-05)
      Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPK alpha 2 but not AMPK alpha 1 Recent studies indicate that the LKB1 is a key regulator of the AMP-activated protein kinase ( AMPK), which plays a ...
    • Defining the prognosis of early stage chronic lymphocytic leukaemia patients 

      Hewamana, Saman (2012-02)
      Approximately 70% of chronic lymphocytic leukaemia (CLL) patients present with early stage disease, therefore defining which patients will progress and require treatment is a major clinical challenge. Here, we present the ...
    • Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes 

      Gruszka-Westwood, AM; Hamoudi, R; Osborne, L; Matutes, E; Catovsky, D (WILEY-LISS, 2003-01)
      Splenic lymphoma with villous lymphocytes (SLVL) is a low-grade lymphoproliferative disorder characterized by splenomegaly and circulating villous lymphocytes in the peripheral blood. It is considered to be the leukemic ...
    • Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia 

      Brito-Babapulle, V; Baou, M; Matutes, E; Morilla, R; Atkinson, S; Catovsky, D (BLACKWELL SCIENCE LTD, 2001-08)
      Deletions of 13q14.3 are well known in several malignancies and are thought to be associated with tumour suppressor function. The RB-1 gene is a tumour suppressor gene, but other loci including D13S319 and D13S25 telomeric ...
    • Delineation of the minimal region of loss at 13q14 in multiple myeloma 

      Elnenaei, MO; Hamoudi, RA; Swansbury, J; Gruszka-Westwood, AM; Brito-Babapulle, V; Matutes, E; Catovsky, D (2003-01)
      Previous studies have focused on the incidence and prognostic implications of 13q14 deletions in multiple myeloma (MM), but none has sought to delineate the minimal common deleted region (CDR). In an effort to do so, ...
    • Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. 

      Watts, E; Heidenreich, D; Tucker, E; Raab, M; Strebhardt, K; Chesler, L; Knapp, S; Bellenie, B; Hoelder, S (2019-03-14)
      Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk ...
    • Designing the future shape of breast cancer diagnosis, prognosis and treatment. 

      Dowsett, M (2004-01)
      Translational research is intended to efficiently and accurately validate the most promising preclinical biomarkers and ensure that their diagnostic or prognostic potential is rapidly adopted in the clinic. Translational ...
    • Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. 

      Davidson, M; Barber, LJ; Woolston, A; Cafferkey, C; Mansukhani, S; Griffiths, B; Moorcraft, S-Y; Rana, I; Begum, R; Assiotis, I; Matthews, N; Rao, S; Watkins, D; Chau, I; Cunningham, D; Starling, N; Gerlinger, M (2019-05-27)
      DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how ...
    • Detecting repeated cancer evolution from multi-region tumor sequencing data. 

      Caravagna, G; Giarratano, Y; Ramazzotti, D; Tomlinson, I; Graham, TA; Sanguinetti, G; Sottoriva, A (2018-09)
      Recurrent successions of genomic changes, both within and between patients, reflect repeated evolutionary processes that are valuable for the anticipation of cancer progression. Multi-region sequencing allows the temporal ...
    • Detecting truly clonal alterations from multi-region profiling of tumours. 

      Werner, B; Traulsen, A; Sottoriva, A; Dingli, D (2017-03-27)
      Modern cancer therapies aim at targeting tumour-specific alterations, such as mutations or neo-antigens, and maximal treatment efficacy requires that targeted alterations are present in all tumour cells. Currently, treatment ...
    • Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry 

      Jain, P; Giustolisi, GM; Atkinson, S; Elnenaei, MO; Morilla, R; Owusu-Ankomah, K; Rafiq-Mohammed, F; Matutes, E; Wotherspoon, A; Catovsky, D (BRITISH MED JOURNAL PUBL GROUP, 2002-12)
      Aims: To describe and revise a flow cytometric assay for evaluating cyclin D1 overexpression in B cell lymphoproliferative disorders (B-LPDs), Methods: Cyclin D1 expression was evaluated in 11 healthy controls and 5 1 ...
    • Detection of the prodrug-activating enzyme carboxypeptidase G2 activity with chemical exchange saturation transfer magnetic resonance. 

      Jamin, Y; Eykyn, TR; Poon, E; Springer, CJ; Robinson, SP (2014-04)
      PURPOSE: The purpose of this study is to evaluate if the differential exchange rates with bulk water between amine and amide protons can be exploited using chemical exchange saturation transfer magnetic resonance (CEST-MR) ...
    • Determinants of age at menarche in the United Kingdom: analyses from the Breakthrough Generations Study 

      Ashworth, A; Jones, M; Schoemaker, M; Swerdlow, A (2010)
      Background: Early menarche increases breast cancer risk but, aside from weight, information on its determinants is limited. Methods: Age at menarche data were collected retrospectively by questionnaire from 81 606 women ...
    • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-19)
      The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ...
    • Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. 

      Izquierdo, E; Yuan, L; George, S; Hubank, M; Jones, C; Proszek, P; Shipley, J; Gatz, SA; Stinson, C; Moore, AS; Clifford, SC; Hicks, D; Lindsey, JC; Hill, RM; Jacques, TS; Chalker, J; Thway, K; O'Connor, S; Marshall, L; Moreno, L; Pearson, A; Chesler, L; Walker, BA; De Castro, DG (2017-12-19)
      The implementation of personalised medicine in childhood cancers has been limited by a lack of clinically validated multi-target sequencing approaches specific for paediatric solid tumours. In order to support innovative ...
    • Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. 

      Molina-Arcas, M; Moore, C; Rana, S; van Maldegem, F; Mugarza, E; Romero-Clavijo, P; Herbert, E; Horswell, S; Li, L-S; Janes, MR; Hancock, DC; Downward, J (2019-09-18)
      KRAS represents an excellent therapeutic target in lung cancer, the most commonly mutated form of which can now be blocked using KRAS-G12C mutant-specific inhibitory trial drugs. Lung adenocarcinoma cells harboring KRAS ...